Efficacy of alprostadil for preventing of contrast-induced nephropathy: A meta-analysis

Abstract Contrast-induced nephropathy (CIN) has become the third-leading cause of hospital-acquired acute renal injury. Although alprostadil has been proposed as an effective preventative measure, this conclusion remains inconsistent. Thus, we performed a meta-analysis of the published studies on th...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Jing-Zhan Zhang, Xiao-Jing Kang, Ying Gao, Ying-Ying Zheng, Ting-Ting Wu, Long Li, Fen Liu, Yi-Ning Yang, Xiao-Mei Li, Yi-Tong Ma, Xiang Xie
Format:	article
Langue:	EN
Publié:	Nature Portfolio 2017
Sujets:	Medicine R Science Q
Accès en ligne:	https://doaj.org/article/62644f8ec04846e4af17cbda1d03a73c
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

id	oai:doaj.org-article:62644f8ec04846e4af17cbda1d03a73c
record_format	dspace
spelling	oai:doaj.org-article:62644f8ec04846e4af17cbda1d03a73c2021-12-02T16:07:57ZEfficacy of alprostadil for preventing of contrast-induced nephropathy: A meta-analysis10.1038/s41598-017-01160-12045-2322https://doaj.org/article/62644f8ec04846e4af17cbda1d03a73c2017-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-01160-1https://doaj.org/toc/2045-2322Abstract Contrast-induced nephropathy (CIN) has become the third-leading cause of hospital-acquired acute renal injury. Although alprostadil has been proposed as an effective preventative measure, this conclusion remains inconsistent. Thus, we performed a meta-analysis of the published studies on this topic to evaluate the preventative effect of alprostadil on CIN. Databases, including PubMed, the Web of Science, Cochrane Library, Wanfang, the China Biological Medicine Database (SinoMed) and the China National Knowledge Infrastructure (CNKI) were systematically searched. Nineteen clinical trials involving 2267 individuals were identified. We utilized a random or a fixed effect model to calculate the pooled odd ratios (ORs) and the standardized mean differences (SMD), respectively. Compared to the control group, the CIN risk decreased significantly in the alprostadil group (P < 0.00001, OR = 0.29, 95% CI = 0.21–0.39). In the subgroup of coronary angiography patients, the use of alprostadil also decreased the risk of CIN (P < 0.00001, OR = 0.27, 95% CI: 0.19–0.39). In conclusion, Alprostadil might be associated with a significant reduction in postcontrast Scr, BUN and CysC level and decrease the incidence of CIN.Jing-Zhan ZhangXiao-Jing KangYing GaoYing-Ying ZhengTing-Ting WuLong LiFen LiuYi-Ning YangXiao-Mei LiYi-Tong MaXiang XieNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-10 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jing-Zhan Zhang Xiao-Jing Kang Ying Gao Ying-Ying Zheng Ting-Ting Wu Long Li Fen Liu Yi-Ning Yang Xiao-Mei Li Yi-Tong Ma Xiang Xie Efficacy of alprostadil for preventing of contrast-induced nephropathy: A meta-analysis
description	Abstract Contrast-induced nephropathy (CIN) has become the third-leading cause of hospital-acquired acute renal injury. Although alprostadil has been proposed as an effective preventative measure, this conclusion remains inconsistent. Thus, we performed a meta-analysis of the published studies on this topic to evaluate the preventative effect of alprostadil on CIN. Databases, including PubMed, the Web of Science, Cochrane Library, Wanfang, the China Biological Medicine Database (SinoMed) and the China National Knowledge Infrastructure (CNKI) were systematically searched. Nineteen clinical trials involving 2267 individuals were identified. We utilized a random or a fixed effect model to calculate the pooled odd ratios (ORs) and the standardized mean differences (SMD), respectively. Compared to the control group, the CIN risk decreased significantly in the alprostadil group (P < 0.00001, OR = 0.29, 95% CI = 0.21–0.39). In the subgroup of coronary angiography patients, the use of alprostadil also decreased the risk of CIN (P < 0.00001, OR = 0.27, 95% CI: 0.19–0.39). In conclusion, Alprostadil might be associated with a significant reduction in postcontrast Scr, BUN and CysC level and decrease the incidence of CIN.
format	article
author	Jing-Zhan Zhang Xiao-Jing Kang Ying Gao Ying-Ying Zheng Ting-Ting Wu Long Li Fen Liu Yi-Ning Yang Xiao-Mei Li Yi-Tong Ma Xiang Xie
author_facet	Jing-Zhan Zhang Xiao-Jing Kang Ying Gao Ying-Ying Zheng Ting-Ting Wu Long Li Fen Liu Yi-Ning Yang Xiao-Mei Li Yi-Tong Ma Xiang Xie
author_sort	Jing-Zhan Zhang
title	Efficacy of alprostadil for preventing of contrast-induced nephropathy: A meta-analysis
title_short	Efficacy of alprostadil for preventing of contrast-induced nephropathy: A meta-analysis
title_full	Efficacy of alprostadil for preventing of contrast-induced nephropathy: A meta-analysis
title_fullStr	Efficacy of alprostadil for preventing of contrast-induced nephropathy: A meta-analysis
title_full_unstemmed	Efficacy of alprostadil for preventing of contrast-induced nephropathy: A meta-analysis
title_sort	efficacy of alprostadil for preventing of contrast-induced nephropathy: a meta-analysis
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/62644f8ec04846e4af17cbda1d03a73c
work_keys_str_mv	AT jingzhanzhang efficacyofalprostadilforpreventingofcontrastinducednephropathyametaanalysis AT xiaojingkang efficacyofalprostadilforpreventingofcontrastinducednephropathyametaanalysis AT yinggao efficacyofalprostadilforpreventingofcontrastinducednephropathyametaanalysis AT yingyingzheng efficacyofalprostadilforpreventingofcontrastinducednephropathyametaanalysis AT tingtingwu efficacyofalprostadilforpreventingofcontrastinducednephropathyametaanalysis AT longli efficacyofalprostadilforpreventingofcontrastinducednephropathyametaanalysis AT fenliu efficacyofalprostadilforpreventingofcontrastinducednephropathyametaanalysis AT yiningyang efficacyofalprostadilforpreventingofcontrastinducednephropathyametaanalysis AT xiaomeili efficacyofalprostadilforpreventingofcontrastinducednephropathyametaanalysis AT yitongma efficacyofalprostadilforpreventingofcontrastinducednephropathyametaanalysis AT xiangxie efficacyofalprostadilforpreventingofcontrastinducednephropathyametaanalysis
_version_	1718384659205718016

Efficacy of alprostadil for preventing of contrast-induced nephropathy: A meta-analysis

Documents similaires